$1.5 million investment round announced to progress COVID -19 clinical trial

We have constructed a term sheet to raise $1.5 million to support a Phase II clinical trial in COVID patients in local Alberta hospitals.  We maintain the current $7.50 share price and $20M company valuation.  Proceeds will be used over the next few months to: Support the purchase of drug components (500 treatment doses) Progress

Read more

Health Canada signs regulatory approval for S-1226 COVID Phase II clinical trial

On the eve of 2021 SolAeroMed received regulatory notification from Health Canada that our proposed clinical trial of S-1226 in COVID patients received official approval. This is approval was a long time coming and SolAeroMed management had been in discussions with Health Canada for 6 months working to address issues around the design of the

Read more

SolAeroMed advances discussion with European partners on development of S-1229 as platform drug technology based on granting of European cyclodextrin patent.

While most of SolAeroMed efforts are focused on advancing clinical trial development of our lead CO2/perflubron S-1226 drug, we have also made recent progress in our S-1229 Cyclodextrin drug technology.   Our pre-clinical and in vitro R&D demonstrates that inhaled cyclodextrin can remove excess cholesterol and repair dysfunctional lung surfactant.  Dysfunctional surfactant is a feature of

Read more

Treatment of Acute Asthma in the ICU

In October 2017 we were able to treat a severely ill asthmatic patient in Calgary ICU with our experimental S1226 drug. Results were in the words of the lead clinician ‘shockingly good’. This case study was presented in May at the American Thoracic Society meeting in San Diego. Full presentation available in poster form.

Read more

SolAeroMed Investment Announcement

CALGARY, AB – December 6, 2016. SolAeroMed Inc. is excited to report a brand new investment opportunity. Please click here to find out more information about our new investment announcement for shares with a warrant.

Read more

SolAeroMed Announces Positive Proof-of-Concept Data for Its Lead Drug (S-1226) in Subjects with Mild Atopic Asthma

CALGARY, Alberta, May 30, 2016 – SolAeroMed Inc. (“SolAeroMed”), a Calgary-based biotechnology company dedicated to developing novel drugs and devices to treat respiratory diseases, today announced positive Phase IIa proof-of-concept results for its S-1226 lead therapeutic. The Phase IIa study was a placebo-controlled, randomized, double-blind, crossover single dose study to evaluate the safety, tolerability and efficacy of S-1226 (8%)

Read more

SolAeroMed Announces Completion of Phase IIA Proof of Concept Recruitment for S-1226

CALGARY, Alberta, November 24, 2015 – SolAeroMed Inc., dedicated to the development of novel therapeutic strategies to treat obstructive lung diseases, today announced its completion of patient recruitment for core components of its Phase IIa Proof of Concept data for its S-1226™ technology by late Fall 2015. “We are very pleased the clinical trial site

Read more

European Respiratory Society Conference

SolAeroMed Inc will be attending the European Thoracic Society conference in Amsterdam, Netherlands to present their S-1226 drug and device technologies. Abstract for S-1226 Drug: We have discovered a new short acting bronchodilator represents a new class of bronchodilator. The drug, S-1226, is made up of a gas (4-12% CO2 in air) combined with a synthetic

Read more

1 2
top